Impact of vessel size, lesion length and diabetes mellitus on angiographic restenosis outcomes: Insights from the NIRTOP study

References

• Fort S, Kornowski R, Silber S, Lewis B, Bilodeau L, Almagor Y, et al. ‘Fused-gold’ versus ‘bare’ stainless steel NIRflex stents of the same geometric design in diseased Native coronary arteries—long term results from the NIRTOP study. Eurointervent in press
   Google Scholar
• Abizaid A, Kornowski R, Mintz GS, Hong MK, Abizaid AS, Mehran R, et al. The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation. J Am Coll Cardiol. 1998; 32: 584–9
   PubMed Web of Science ®Google Scholar
• Cutlip DE, Chauhan MS, Baim DS, Ho KK, Popma JJ, Carrozza JP, et al. Clinical restenosis after coronary stenting: perspectives from multicenter clinical trials. J Am Coll Cardiol. 2002; 40: 2082–9
   PubMed Web of Science ®Google Scholar
• Singh M, Gersh BJ, McClelland RL, Ho KK, Willerson JT, Penny WF, et al. Clinical and angiographic predictors of restenosis after percutaneous coronary intervention: insights from the prevention of restenosis with tranilast and its outcomes (PRESTO) trial. Circulation 2004; 109: 2727–31
   PubMed Web of Science ®Google Scholar
• Mazeika P, Prasad N, Bui S, Seidelin PH. Predictors of angiographic restenosis after coronary intervention in patients with diabetes mellitus. Am Heart J. 2003; 145: 1013–21
   PubMedGoogle Scholar
• Serruys P, Foley DP, de Feyter PJ. Quantitative coronary angiography in clinical practice. Kluwer Academic, Dordrechtthe Netherlands 1994
   Google Scholar
• Ruygrok PN, Webster MW, Ardill JJ, Chan CC, Mak KH, Meredith IT, et al. Vessel caliber and restenosis: a prospective clinical and angiographic study of NIR stent deployment in small and large coronary arteries in the same patient. Catheter Cardiovasc Interv. 2003; 59: 165–71
   PubMed Web of Science ®Google Scholar
• Hoffmann R, Mintz GS, Pichard AD, Kent KM, Satler LF, Leon MB. Intimal hyperplasia thickness at follow-up is independent of stent size: a serial intravascular ultrasound study. Am J Cardiol. 1998; 82: 1168–72
   PubMed Web of Science ®Google Scholar
• Mintz GS, Popma JJ, Pichard AD, Kent KM, Satler LF, Hong MK, et al. Intravascular ultrasound assessment of the mechanisms and predictors of restenosis following coronary angioplasty. J Invasive Cardiol. 1997; 9: 303–14
   PubMed Web of Science ®Google Scholar
• Rogers C, Edelman ER. Endovascular stent design dictates experimental restenosis and thrombosis. Circulation 1995; 91: 2995–3001
   PubMed Web of Science ®Google Scholar
• Edelman ER, Rogers C. Stent-versus-stent equivalency trials: are some stents more equal than others?. Circulation 1999; 100: 896–8
   PubMedGoogle Scholar
• Fajadet J, Wijns W, Laarman GJ, Kuck KH, Ormiston J, Munzel T, et al. ENDEAVOR II Investigators. Randomized, double-blind, multicenter study of the endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial. Circulation 2006; 114: 798–806
   PubMed Web of Science ®Google Scholar
• Kornowski R, Lansky AJ. Current perspectives on interventional treatment strategies in diabetic patients with coronary artery disease. Catheter Cardiovasc Interv. 2000; 50: 245–54
   PubMed Web of Science ®Google Scholar
• Safley DM, Marso SP. Diabetes and percutaneous coronary revascularization in the drug-eluting stent era. Herz. 2004; 29: 542–50
   PubMedGoogle Scholar
• Lemos PA, Hoye A, Goedhart D, Arampatzis CA, Saia F, van der Giessen WJ, et al. Clinical, angiographic, and procedural predictors of angiographic restenosis after sirolimus-eluting stent implantation in complex patients: an evaluation from the rapamycin-eluting stent evaluated at Rotterdam cardiology hospital (RESEARCH) study. Circulation 2004; 109: 1366–70
   PubMed Web of Science ®Google Scholar
• Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003; 349: 1315–23
   PubMed Web of Science ®Google Scholar
• Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, et al. TAXUS-IV Investigators. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med. 2004; 350: 221–31
   PubMed Web of Science ®Google Scholar
• Spaulding C, Daemen J, Boersma E, Cutlip DE, Serruys PW. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med. 2007; 356: 989–97
   PubMed Web of Science ®Google Scholar
• Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, et al. RAVEL Study Group. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. Randomized study with the sirolimus-coated Bx velocity balloon-expandable stent in the treatment of patients with de novo native coronary artery lesions. N Engl J Med. 2002; 346: 1773–80
   PubMed Web of Science ®Google Scholar
• Abizaid A, Costa MA, Blanchard D, Albertal M, Eltchaninoff H, Guagliumi G, et al. Ravel Investigators. Sirolimus-eluting stents inhibit neointimal hyperplasia in diabetic patients. Insights from the RAVEL Trial. Eur Heart J. 2004; 25: 107–12
   PubMed Web of Science ®Google Scholar
• Sabaté M, Jiménez-Quevedo P, Angiolillo DJ, Alfonso F, Bañuelos C, Goicolea J, et al. DIABETES and sirolimus eluting stent trial. Presented at TCT Meeting 9/2004.
   Google Scholar
• Rozenman Y, Sapoznikov D, Mosseri M, Gilon D, Lotan C, Nassar H, et al. Long-term angiographic follow-up of coronary balloon angioplasty in patients with diabetes mellitus: a clue to the explanation of the results of the BARI study. Balloon angioplasty revascularization investigation. J Am Coll Cardiol. 1997; 30: 1420–5
   PubMed Web of Science ®Google Scholar
• Kornowski R, Fuchs S. Optimization of glycemic control and restenosis prevention in diabetic patients undergoing percutaneous coronary interventions J Am Coll Cardiol. 2004; 43: 15–7
   Google Scholar